Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

Form 4 May 25, 201		FICALS I	NC							
FORM	14_{UNITED}	STATES	SECU	RITIFS /	AND FX	CHANGE	COMMISSION	r	PPROVAL	
	SIAILS	S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					OMB Number:	3235-0287		
Check the if no long	ter.								January 31,	
subject to Section 1 Form 4 o	.6. SIAIEN	MENT OI	F CHAN	NGES IN SECUI		TCIAL OV	WNERSHIP OF	Expires: Estimated burden hou	urs per	
Form 5 obligation may cont See Instru 1(b).	Filed pur ns Section 17((a) of the l	Public U	Itility Hol	ding Co		nge Act of 1934, of 1935 or Sectio 940	n response	. 0.5	
(Print or Type I	Responses)									
1. Name and Address of Reporting Person <u>*</u> Babu Yarlagadda S			2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICAL			5. Relationship of Reporting Person(s) to Issuer				
			INC [B	CRX]			(Cnec	k all applicabl	e)	
(Last)	(First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)				Director10% Owner Officer (give titleOther (specify below)below)					
4505 EMPEROR BLVD., SUITE 200			05/23/2016				Senior VP - Drug Discovery			
DURHAM,	(Street) NC 27703			endment, D onth/Day/Yea	-	ıl	6. Individual or Jo Applicable Line) _X_ Form filed by M Form filed by M Person		erson	
(City)	(State)	(Zip)	Tah	le I - Non-l	Dorivativa	Securities A	cquired, Disposed o	f or Bonoficia	lly Owned	
1.Title of	2. Transaction Date	24 Deem		3.	4. Securi			5. Ownership	7. Nature of	
Security	(Month/Day/Year)			Transactio	onAcquired	(A) or	Securities I	Form: Direct	Indirect	
(Instr. 3)		any (Month/Da	w/Vear)	Code (Instr. 8)	Disposed (Instr. 3,			D) or Indirect	Beneficial Ownership	
		(MOILIND)	iy/ I cai)	(11150.0)	(111501. 5,	+ and <i>5)</i>	· · · · · · · · · · · · · · · · · · ·	1) Instr. 4)	(Instr. 4)	
						(A)	Reported			
				<u> </u>		or	Transaction(s) (Instr. 3 and 4)			
				Code V	Amount	(D) Price				
Reminder: Rep	ort on a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly o	or indirectly.			
					inforr requi	nation cont red to respo ays a curre	spond to the collec ained in this form ond unless the for ntly valid OMB cor	are not m	SEC 1474 (9-02)	
	Tab					sposed of, or convertible s	Beneficially Owned securities)			
1. Title of 2. Derivative C		saction Date /Day/Year)			4. Transact	5. Number iorDerivative			7. Title and Amount of Underlying Securities	

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) of Disposed of (E (Instr. 3, 4, and 5)	(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A) (I) Date Exercisable	Expiration Date	Title	Amount o Number o Shares
Emp. Stock Option (Right to Buy)	\$ 3.22	05/23/2016		А	129,427 (1)	05/23/2017	05/23/2026	Common Stock	129,42′

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Babu Yarlagadda S 4505 EMPEROR BLVD. SUITE 200 DURHAM, NC 27703			Senior VP - Drug Discovery				
Signatures							
/s/ Alane P. Barnes, by power of attorney	of	05/25	5/2016				

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Retention Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.